pramlintide metreleptin Search Results


pramlintide (combined with metreleptin) or placebo  (AstraZeneca ltd)
90
AstraZeneca ltd pramlintide (combined with metreleptin) or placebo
Ongoing clinical trials in obesity and/or overweight using amylin analogs or Celastrol (up to 16 October 2024).
Pramlintide (Combined With Metreleptin) Or Placebo, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pramlintide+metreleptin/pramlintide++combined+with+metreleptin++or+placebo/pmc11591892-8-5-37
Average 90 stars, based on 1 article reviews
pramlintide (combined with metreleptin) or placebo - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
metreleptin pramlintide clinical program  (Amgen)
86
Amgen metreleptin pramlintide clinical program
Ongoing clinical trials in obesity and/or overweight using amylin analogs or Celastrol (up to 16 October 2024).
Metreleptin Pramlintide Clinical Program, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pramlintide+metreleptin/clinical+metreleptin+pramlintide+program/fda_document____drugsatfda_docs_slash_nda_slash_2014_slash_125390orig1s000admincorres-959-3-11
Average 86 stars, based on 1 article reviews
metreleptin pramlintide clinical program - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Ongoing clinical trials in obesity and/or overweight using amylin analogs or Celastrol (up to 16 October 2024).

Journal: Biomedicines

Article Title: Hippocampal Leptin Resistance and Cognitive Decline: Mechanisms, Therapeutic Strategies and Clinical Implications

doi: 10.3390/biomedicines12112422

Figure Lengend Snippet: Ongoing clinical trials in obesity and/or overweight using amylin analogs or Celastrol (up to 16 October 2024).

Article Snippet: 8 , NCT01235741 II/RDBPC , Pramlintide (combined with Metreleptin) or placebo , Obesity , Effect of 16 weeks of treatment on body weight in subjects with obesity. Studies of safety and tolerability of the drug combination. , AstraZeneca , Terminated , 15 April 2015.

Techniques: Clinical Proteomics, Drug discovery